Tahir Amin
@tahiramin.bsky.social
CEO @imakglobal.bsky.social. Renegade IP lawyer. Critically rethinking IP laws through (neo)colonial/neoliberal systems of power, and that empty word “innovation”.
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
November 19, 2025 at 3:10 PM
Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.
Great to see Lina Khan teaching folks about Orange Book abuse.
November 19, 2025 at 3:00 PM
Great to see Lina Khan teaching folks about Orange Book abuse.
At what point does combining an existing biologic drug with a form of hyaluronidase to create an injectable formulation become obvious?🧵
October 15, 2025 at 10:26 PM
At what point does combining an existing biologic drug with a form of hyaluronidase to create an injectable formulation become obvious?🧵
Hyaluronidase (the ingredient Merck added to create the SC version of Keytruda) has been used by plenty of other companies to enable SC delivery. It’s not exactly something that wasn’t known…
October 13, 2025 at 11:01 PM
Hyaluronidase (the ingredient Merck added to create the SC version of Keytruda) has been used by plenty of other companies to enable SC delivery. It’s not exactly something that wasn’t known…
Subcutaneous versions of IV drugs often launch right around the time that IV patents expire. What a mysterious phenomenon…
October 6, 2025 at 5:24 PM
Subcutaneous versions of IV drugs often launch right around the time that IV patents expire. What a mysterious phenomenon…
When facts are not on your side, desperation sets in 🙃
September 19, 2025 at 10:45 PM
When facts are not on your side, desperation sets in 🙃
🎯“Moreover, the rhetoric of innovation is frequently weaponized to resist regulation, even as many so-called innovations yield minimal therapeutic gains.”
August 27, 2025 at 9:28 PM
🎯“Moreover, the rhetoric of innovation is frequently weaponized to resist regulation, even as many so-called innovations yield minimal therapeutic gains.”
From dodging domestic taxes to abusing the patent system to price gouging patients in the U.S and abroad. The list is endless. No one is better at ripping off the public than multinational pharma companies.
August 20, 2025 at 9:40 PM
From dodging domestic taxes to abusing the patent system to price gouging patients in the U.S and abroad. The list is endless. No one is better at ripping off the public than multinational pharma companies.
In June, we added 10 new products to the database: Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Farxiga, Entresto, Jardiance, Januvia, and Xarelto. It now covers 20 products and 1,219 related patents we’ve identified.
August 20, 2025 at 8:37 PM
In June, we added 10 new products to the database: Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Farxiga, Entresto, Jardiance, Januvia, and Xarelto. It now covers 20 products and 1,219 related patents we’ve identified.
The three speakers on this IP Watchdog panel, one of whom is the Head of IP Policy at Amgen, will supposedly “walk through the real data behind drug patent portfolios”. Spoiler alert: they won’t.
August 20, 2025 at 8:37 PM
The three speakers on this IP Watchdog panel, one of whom is the Head of IP Policy at Amgen, will supposedly “walk through the real data behind drug patent portfolios”. Spoiler alert: they won’t.
PhRMA is teaming up with other industry mouthpieces including IP Watchdog and IP law firms to host a panel smearing I-MAK. I guess branded drug companies don’t like having their go-to monopolization tactics exposed.🧵
August 20, 2025 at 8:37 PM
PhRMA is teaming up with other industry mouthpieces including IP Watchdog and IP law firms to host a panel smearing I-MAK. I guess branded drug companies don’t like having their go-to monopolization tactics exposed.🧵
Patent reform. An issue with growing bipartisan support.
July 29, 2025 at 6:19 PM
Patent reform. An issue with growing bipartisan support.
AbbVie offered technical employees iPhones, iPads, and Apple computers as rewards for coming up with new ideas to "increase the patent coverage for Humira."
July 23, 2025 at 9:42 PM
AbbVie offered technical employees iPhones, iPads, and Apple computers as rewards for coming up with new ideas to "increase the patent coverage for Humira."
"AbbVie executives circulated a presentation further emphasizing that one objective of the 'enhancement' strategy was to 'raise barriers to competitor ability to replicate.'"
July 23, 2025 at 9:42 PM
"AbbVie executives circulated a presentation further emphasizing that one objective of the 'enhancement' strategy was to 'raise barriers to competitor ability to replicate.'"
"Mr. Gonzalez took McKinsey's advice to heart. A few months after receiving McKinsey's recommendations, he sent his team a memorandum directing them to redouble their efforts to develop 'enhancements' to Humira."
July 23, 2025 at 9:42 PM
"Mr. Gonzalez took McKinsey's advice to heart. A few months after receiving McKinsey's recommendations, he sent his team a memorandum directing them to redouble their efforts to develop 'enhancements' to Humira."
The first actions McKinsey recommended that AbbVie take were to “differentiate the product through extensions/next-gen products” and “delay biosimilars through legal/lobbying actions”.
July 23, 2025 at 9:42 PM
The first actions McKinsey recommended that AbbVie take were to “differentiate the product through extensions/next-gen products” and “delay biosimilars through legal/lobbying actions”.
In a recent FTC listening session, Hans Sauer of BIO suggested that pharma execs don’t coordinate with lawyers to strategically use patents to block competition. I guess he forgot about the Congressional investigation exposing how AbbVie hired McKinsey to do exactly that.
July 23, 2025 at 9:42 PM
In a recent FTC listening session, Hans Sauer of BIO suggested that pharma execs don’t coordinate with lawyers to strategically use patents to block competition. I guess he forgot about the Congressional investigation exposing how AbbVie hired McKinsey to do exactly that.
Thank you to The Plus SideZ podcast for having me on to talk about the patent system and how the pharma industry’s abuse of it keeps GLP-1 prices so high.
July 16, 2025 at 5:28 PM
Thank you to The Plus SideZ podcast for having me on to talk about the patent system and how the pharma industry’s abuse of it keeps GLP-1 prices so high.
The shadow org flunked Senators Peter Welch and Maggie Hassan. Probably bc they’ve been grilling pharma CEOs in Congressional hearings and trying to close loopholes in the patent system that the pharma industry currently exploits to jack up drug prices.
June 25, 2025 at 5:05 PM
The shadow org flunked Senators Peter Welch and Maggie Hassan. Probably bc they’ve been grilling pharma CEOs in Congressional hearings and trying to close loopholes in the patent system that the pharma industry currently exploits to jack up drug prices.
Unsurprisingly, two of the biggest recipients of pharma $, Senators Chris Coons (D-DE) and Thom Tillis (R-NC), each earned an A+
June 25, 2025 at 5:05 PM
Unsurprisingly, two of the biggest recipients of pharma $, Senators Chris Coons (D-DE) and Thom Tillis (R-NC), each earned an A+
A patent-maximalist “think tank” run by revolving door insiders graded members of Congress on how “pro-IP” they are. A creative way to let PhRMA and other lobbyists know which members they should grease to continue financialising the IP system.
June 25, 2025 at 5:05 PM
A patent-maximalist “think tank” run by revolving door insiders graded members of Congress on how “pro-IP” they are. A creative way to let PhRMA and other lobbyists know which members they should grease to continue financialising the IP system.
Our updated and expanded version of The Drug Patent Book now holds patent data on 20 top-selling drugs, some of which will be included in the next round of Medicare negotiations.
drugpatentbook.i-mak.org
drugpatentbook.i-mak.org
June 17, 2025 at 3:39 PM
Our updated and expanded version of The Drug Patent Book now holds patent data on 20 top-selling drugs, some of which will be included in the next round of Medicare negotiations.
drugpatentbook.i-mak.org
drugpatentbook.i-mak.org
Our new report reveals the systemic flaws in our patent system that are allowing drug companies to drive up the price of Eliquis, a top-selling blood thinner, and the semaglutide family of diabetes and weight-loss drugs including Ozempic, Rybelsus, and Wegovy.
www.i-mak.org/overpatented/
www.i-mak.org/overpatented/
June 17, 2025 at 3:39 PM
Our new report reveals the systemic flaws in our patent system that are allowing drug companies to drive up the price of Eliquis, a top-selling blood thinner, and the semaglutide family of diabetes and weight-loss drugs including Ozempic, Rybelsus, and Wegovy.
www.i-mak.org/overpatented/
www.i-mak.org/overpatented/
Pages 35-36: Krause calls out how a 2024 USPTO report is “misleadingly used to deny the undeniable facts of drug company evergreening and drug pricing practices.”
June 5, 2025 at 6:10 PM
Pages 35-36: Krause calls out how a 2024 USPTO report is “misleadingly used to deny the undeniable facts of drug company evergreening and drug pricing practices.”
Page 12: Krause explains how drug companies use the patent system to help them charge high drug prices
June 5, 2025 at 6:10 PM
Page 12: Krause explains how drug companies use the patent system to help them charge high drug prices